One CAR-T infusion instead of autologous transplant
Replace high-dose melphalan and stem-cell rescue with a single infusion of the patient's engineered T cells after induction.
CARTITUDE-6 (EMagine) randomises Dara-VRd → cilta-cel versus Dara-VRd → transplant; CARTITUDE-5 tests cilta-cel as consolidation where transplant is not planned. CARTITUDE-1 shows a third of late-line patients progression-free at 5 years without maintenance.
Pages like this
not linked directly; found by shared links- TrialCARTITUDE-1
Shares Ciltacabtagene autoleucel, Multiple myeloma, CAR-T cell therapy.
- Key paperCARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy
Shares CARTITUDE-5, CARTITUDE-4, Ciltacabtagene autoleucel, Multiple myeloma.
- PersonJohn F. DiPersio
Shares Autologous stem cell transplant (high-dose therapy), Multiple myeloma, CAR-T cell therapy.
- IdeaPay-for-cure contracts: instalment payments for curative therapies contingent on durable remission
- IdeaMandatory public reporting of vein-to-vein time and failure rate per CAR-T product
- InstitutionIUCT Oncopole – Institut Universitaire du Cancer de Toulouse
Shares Ciltacabtagene autoleucel, Multiple myeloma, CAR-T cell therapy.
- CompanyLegend Biotech
- PersonPaul G. Richardson
Shares Autologous stem cell transplant (high-dose therapy), Multiple myeloma.